Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia

L. Laue, J. M. Hoeg, K. Barnes, J. L. Ross, Donald (Lynn) Loriaux, G. P. Chrousos

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Growth hormone secretory dynamics and plasma somatomedin C concentrations were assessed in four prepubertal patients with defects in the low-density lipoprotein (LDL) receptor pathway before and after 2 months of treatment with mevinolin, an HMG-CoA reductase inhibitor that reduces intracellular cholesterol. Pre- and posttreatment mean 24-hour growth hormone levels and pulse amplitude were similar and tended to be higher than in age-matched prepubertal controls. Pre- and posttreatment somatomedin C levels were also similar and lower than in age-matched prepubertal controls. All patients responded to growth hormone provocative testing with a peak response of greater than 7 ng/ml, independent of treatment status. Growth velocity was not significantly altered in any patient following 2 months of treatment with mevinolin, and was wihin the normal range for age. Thus, children with defects in the LDL receptor pathway express abnormalities in growth hormone secretion and somatomedin C generation comparable to those seen in other chronic diseases. Treatment with mevinolin has no apparent effect on these biochemical abnormalities, suggesting that it may not have long-term effects on growth. Regardless of mevinolin therapy, children with defects in the LDL receptor pathway may manifest a degree of growth retardation and, hence, growth rate and skeletal maturation should be closely monitored.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalHormone Research
Volume29
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type II
Lovastatin
Growth Hormone
LDL Receptors
Insulin-Like Growth Factor I
Growth
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Reference Values
Chronic Disease
Cholesterol

ASJC Scopus subject areas

  • Endocrinology

Cite this

Laue, L., Hoeg, J. M., Barnes, K., Ross, J. L., Loriaux, D. L., & Chrousos, G. P. (1988). Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia. Hormone Research, 29(1), 23-26.

Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia. / Laue, L.; Hoeg, J. M.; Barnes, K.; Ross, J. L.; Loriaux, Donald (Lynn); Chrousos, G. P.

In: Hormone Research, Vol. 29, No. 1, 1988, p. 23-26.

Research output: Contribution to journalArticle

Laue, L, Hoeg, JM, Barnes, K, Ross, JL, Loriaux, DL & Chrousos, GP 1988, 'Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia', Hormone Research, vol. 29, no. 1, pp. 23-26.
Laue, L. ; Hoeg, J. M. ; Barnes, K. ; Ross, J. L. ; Loriaux, Donald (Lynn) ; Chrousos, G. P. / Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia. In: Hormone Research. 1988 ; Vol. 29, No. 1. pp. 23-26.
@article{303b2c4355354b809deb3ede39474cf4,
title = "Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia",
abstract = "Growth hormone secretory dynamics and plasma somatomedin C concentrations were assessed in four prepubertal patients with defects in the low-density lipoprotein (LDL) receptor pathway before and after 2 months of treatment with mevinolin, an HMG-CoA reductase inhibitor that reduces intracellular cholesterol. Pre- and posttreatment mean 24-hour growth hormone levels and pulse amplitude were similar and tended to be higher than in age-matched prepubertal controls. Pre- and posttreatment somatomedin C levels were also similar and lower than in age-matched prepubertal controls. All patients responded to growth hormone provocative testing with a peak response of greater than 7 ng/ml, independent of treatment status. Growth velocity was not significantly altered in any patient following 2 months of treatment with mevinolin, and was wihin the normal range for age. Thus, children with defects in the LDL receptor pathway express abnormalities in growth hormone secretion and somatomedin C generation comparable to those seen in other chronic diseases. Treatment with mevinolin has no apparent effect on these biochemical abnormalities, suggesting that it may not have long-term effects on growth. Regardless of mevinolin therapy, children with defects in the LDL receptor pathway may manifest a degree of growth retardation and, hence, growth rate and skeletal maturation should be closely monitored.",
author = "L. Laue and Hoeg, {J. M.} and K. Barnes and Ross, {J. L.} and Loriaux, {Donald (Lynn)} and Chrousos, {G. P.}",
year = "1988",
language = "English (US)",
volume = "29",
pages = "23--26",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Abnormal growth hormone secretory dynamics in children with familial hypercholesterolemia

AU - Laue, L.

AU - Hoeg, J. M.

AU - Barnes, K.

AU - Ross, J. L.

AU - Loriaux, Donald (Lynn)

AU - Chrousos, G. P.

PY - 1988

Y1 - 1988

N2 - Growth hormone secretory dynamics and plasma somatomedin C concentrations were assessed in four prepubertal patients with defects in the low-density lipoprotein (LDL) receptor pathway before and after 2 months of treatment with mevinolin, an HMG-CoA reductase inhibitor that reduces intracellular cholesterol. Pre- and posttreatment mean 24-hour growth hormone levels and pulse amplitude were similar and tended to be higher than in age-matched prepubertal controls. Pre- and posttreatment somatomedin C levels were also similar and lower than in age-matched prepubertal controls. All patients responded to growth hormone provocative testing with a peak response of greater than 7 ng/ml, independent of treatment status. Growth velocity was not significantly altered in any patient following 2 months of treatment with mevinolin, and was wihin the normal range for age. Thus, children with defects in the LDL receptor pathway express abnormalities in growth hormone secretion and somatomedin C generation comparable to those seen in other chronic diseases. Treatment with mevinolin has no apparent effect on these biochemical abnormalities, suggesting that it may not have long-term effects on growth. Regardless of mevinolin therapy, children with defects in the LDL receptor pathway may manifest a degree of growth retardation and, hence, growth rate and skeletal maturation should be closely monitored.

AB - Growth hormone secretory dynamics and plasma somatomedin C concentrations were assessed in four prepubertal patients with defects in the low-density lipoprotein (LDL) receptor pathway before and after 2 months of treatment with mevinolin, an HMG-CoA reductase inhibitor that reduces intracellular cholesterol. Pre- and posttreatment mean 24-hour growth hormone levels and pulse amplitude were similar and tended to be higher than in age-matched prepubertal controls. Pre- and posttreatment somatomedin C levels were also similar and lower than in age-matched prepubertal controls. All patients responded to growth hormone provocative testing with a peak response of greater than 7 ng/ml, independent of treatment status. Growth velocity was not significantly altered in any patient following 2 months of treatment with mevinolin, and was wihin the normal range for age. Thus, children with defects in the LDL receptor pathway express abnormalities in growth hormone secretion and somatomedin C generation comparable to those seen in other chronic diseases. Treatment with mevinolin has no apparent effect on these biochemical abnormalities, suggesting that it may not have long-term effects on growth. Regardless of mevinolin therapy, children with defects in the LDL receptor pathway may manifest a degree of growth retardation and, hence, growth rate and skeletal maturation should be closely monitored.

UR - http://www.scopus.com/inward/record.url?scp=0023944269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023944269&partnerID=8YFLogxK

M3 - Article

C2 - 3397039

AN - SCOPUS:0023944269

VL - 29

SP - 23

EP - 26

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 1

ER -